Cargando…

Systemic adjuvant therapies in renal cell carcinoma

Renal cell carcinoma (RCC) is one of the ten most frequent solid tumors worldwide. Recent innovations in the treatment of metastatic disease have led to new therapeutic approaches being investigated in the adjuvant setting. Observation is the only current standard of care after radical nephrectomy,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buti, Sebastiano, Bersanelli, Melissa, Donini, Maddalena, Ardizzoni, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419621/ https://www.ncbi.nlm.nih.gov/pubmed/25992216 http://dx.doi.org/10.4081/oncol.2012.e18

Ejemplares similares

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
por: Bersanelli, Melissa, et al.
Publicado: (2017)

Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study
por: Buti, Sebastiano, et al.
Publicado: (2017)

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy
por: Buti, Sebastiano, et al.
Publicado: (2016)

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study
por: Buti, Sebastiano, et al.
Publicado: (2018)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
por: Bersanelli, Melissa, et al.
Publicado: (2018)

Renal cell carcinoma and viral infections: A dangerous relationship?
por: Bersanelli, Melissa, et al.
Publicado: (2022)

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
por: Leonetti, Alessandro, et al.
Publicado: (2017)

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review
por: Bersanelli, Melissa, et al.
Publicado: (2020)

From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis
por: Bersanelli, Melissa, et al.
Publicado: (2017)

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?
por: Taguchi, Satoru, et al.
Publicado: (2017)

Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials
por: Bersanelli, Melissa, et al.
Publicado: (2021)

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
por: Cattrini, Carlo, et al.
Publicado: (2021)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Family history of cancer and DNA damage response genes: Two sides of the same coin?
por: Cortellini, Alessio, et al.
Publicado: (2018)

Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?
por: Cosso, Federica, et al.
Publicado: (2023)

Differential diagnosis of COVID-19 at the chest computed tomography scan: A review with special focus on cancer patients
por: Perrone, Fabiana, et al.
Publicado: (2021)

Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date
por: Tacconi, Eliana M C, et al.
Publicado: (2020)

The Continuing Question of Adjuvant Therapy in Clear Cell Renal Cell Carcinoma
por: Berg, Stephanie A., et al.
Publicado: (2022)

Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients
por: Buti, Sebastiano, et al.
Publicado: (2019)

Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients
por: Buti, Sebastiano, et al.
Publicado: (2020)

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy
por: Bersanelli, Melissa, et al.
Publicado: (2014)

Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy
por: Mattila, Kalle E., et al.
Publicado: (2022)

Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?
por: Rossi, Ernesto, et al.
Publicado: (2021)

Review on radiological evolution of COVID-19 pneumonia using computed tomography
por: Casartelli, Chiara, et al.
Publicado: (2021)

The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
por: Buti, Sebastiano, et al.
Publicado: (2022)

Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?
por: Mollica, Veronica, et al.
Publicado: (2021)

First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series
por: Buti, Sebastiano, et al.
Publicado: (2021)

Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction
por: Buller, Dylan M, et al.
Publicado: (2023)

Adjuvant Therapy in Renal Cell Carcinoma—Past, Present, and Future()
por: Janowitz, Tobias, et al.
Publicado: (2013)

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
por: Stellato, Marco, et al.
Publicado: (2023)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Adjuvant therapy for renal cell carcinoma, finally a new standard?
por: Renner, Alex, et al.
Publicado: (2022)

The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients
por: Bersanelli, Melissa, et al.
Publicado: (2021)

Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy
por: Bottiglieri, Achille, et al.
Publicado: (2022)

Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Systemic therapy in metastatic renal cell carcinoma
por: Bedke, Jens, et al.
Publicado: (2016)

Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab
por: Bersanelli, Melissa, et al.
Publicado: (2019)

Adjuvant Therapy for Esophageal Squamous Cell Carcinoma
por: Sun, Jong-Mu
Publicado: (2020)

Lipids as Targets for Renal Cell Carcinoma Therapy
por: Stepanovska Tanturovska, Bisera, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3ra9jtlfjccqj2ebntfttqljjh